<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04690894</url>
  </required_header>
  <id_info>
    <org_study_id>266:7/2019</org_study_id>
    <nct_id>NCT04690894</nct_id>
  </id_info>
  <brief_title>Erector Spinae Muscle Block Versus Caudal Block by Sonar in Pediatrics Undergoing Lower Abdominal Surgery</brief_title>
  <official_title>Ultrasound-guided Erector Spinae Muscle Block Versus Ultrasound-guided Caudal Block in Pediatric Patient Undergoing Lower Abdominal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minia University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      this prospective randomized double blind controlled study was conducted on 60 child scheduled&#xD;
      for lower abdominal surgery under general anesthesia. the patients were randomly allocated&#xD;
      into 3 parallel groups.group (ESB) patients received ultrasound-guided erector spinae block&#xD;
      in a dose of 0.4mg/ml of 0.25%bupivacaine between the 10th transverse process and erector&#xD;
      spinae muscles.group(CB) patients received ultrasound-guided caudal block in a dose of&#xD;
      2.5mg/kg of 0.25%bupivacaine. group(CO) did,t received any block&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      on arrival of the patients to the operative theatre and after placement of the standard&#xD;
      monitoring general inhalational anesthesia was induced by face mask with sevoflurane (4-8%)&#xD;
      in oxygen after IV cannula was secured patients received 1mic/kg fentanyl and intubation was&#xD;
      facilitated by 0.5mg/kg atracurium. isoflurane 1-2% with oxygen was used for maintenance of&#xD;
      anesthesia. after stabilization of the patient's hemodynamics and before skin incision&#xD;
      erector spinae block or caudal block was performed with the patient in lateral position.&#xD;
      after the block patients were flipped back to their normal supine position, surgery took&#xD;
      place 10 min after injection of local anesthetic. after termination of surgery reversal of&#xD;
      the atracurium was done by giving neostigmine in a dose of 0.04mg/kg and atropine 0.02mg/kg&#xD;
      and awake extubation was done&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 15, 2019</start_date>
  <completion_date type="Actual">February 15, 2020</completion_date>
  <primary_completion_date type="Actual">January 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients need rescue analgesia</measure>
    <time_frame>24 hours</time_frame>
    <description>total number of patients need addition of anagesia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>First analgesic request</measure>
    <time_frame>24 hours</time_frame>
    <description>First time that patient require analgesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic changes in the study period</measure>
    <time_frame>24 hours</time_frame>
    <description>Changes in HR and blood pressure</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Postoperative Analgesia</condition>
  <arm_group>
    <arm_group_label>Erector spinae group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the child received ultrasound-guided erector spinae muscle block in a dose of 0.4mg/kg of 0.25%bupivacaine between the 10th transverse process and erector spinae muscle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>caudal group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>child received ultrasound-guided caudal block in a dose of 2.5mg/kg of bupivacaine 0.25%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>child didn't received any regional block</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>erector spinae block - caudal block</intervention_name>
    <description>the child placed in lateral position identification of spinous process of 10th thoracic vertebral then the transducer was moved 2.5 cm laterally to visualize the transverse process and a total of 0.4mg/kg of 0.25%bupivacaine was adminstered</description>
    <arm_group_label>Erector spinae group</arm_group_label>
    <arm_group_label>caudal group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  pediatric patients aged 2-6 years scheduled for lower abdominal surgery under general&#xD;
             anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  parent refusal&#xD;
&#xD;
          -  spinal and meningeal anomalies&#xD;
&#xD;
          -  mental retardation&#xD;
&#xD;
          -  blood disease&#xD;
&#xD;
          -  infection at site of injection&#xD;
&#xD;
          -  drug allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ibrahim Talaat, MD</last_name>
    <role>Study Director</role>
    <affiliation>professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Minya</city>
        <zip>61111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>December 28, 2020</study_first_submitted>
  <study_first_submitted_qc>December 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Minia University</investigator_affiliation>
    <investigator_full_name>Shadwa Rabea Mohamed</investigator_full_name>
    <investigator_title>lecturer</investigator_title>
  </responsible_party>
  <pending_results>
    <submitted>March 17, 2021</submitted>
    <returned>April 12, 2021</returned>
    <submitted>June 1, 2021</submitted>
    <returned>June 22, 2021</returned>
    <submitted>July 19, 2021</submitted>
    <returned>August 12, 2021</returned>
    <submitted>September 9, 2021</submitted>
    <returned>October 6, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

